Cancer cell genome

The cancer cell genome represents the entire set of genetic instructions within a malignant cell, characterized by profound alterations including point mutations, translocations, and large-scale chromosomal instability (National Cancer Institute, 2023). These genomic changes drive the initiation, progression, and therapeutic resistance of tumors by altering the expression and function of key regulatory proteins (Hanahan & Weinberg, 2011). While the genome is a complex assembly of thousands of genes rather than a single molecular target, it serves as the fundamental substrate for various cytotoxic therapies, such as platinum-based agents and alkylators, which disrupt DNA integrity to halt tumor growth (NIH PubChem, 2024). Modern oncology increasingly relies on the cancer genome as a diagnostic and prognostic tool, utilizing high-throughput sequencing to identify actionable mutations and calculate metrics like Tumor Mutational Burden (TMB) (Nature Reviews Cancer, 2019). Furthermore, the advent of gene-editing technologies has opened new avenues for directly correcting or eliminating pathogenic sequences within the cancer genome, moving beyond non-specific DNA damage toward precise genetic intervention (PubMed, 2022).

Other names

Tumor genomeCancer genomeMalignant cell DNAOncogenome

Drugs targeting the cancer cell genome primarily function by inducing irreversible DNA damage, such as interstrand cross-links or double-strand breaks, which overwhelm the cell's repair mechanisms and trigger programmed cell death (StatPearls, 2023). Other agents, such as topoisomerase inhibitors, interfere with the structural maintenance of the genome during replication, while emerging gene-editing technologies like CRISPR-Cas9 allow for the precise modification or deletion of oncogenic sequences (Nature, 2022).